Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

HIV: KOL Insight

Product Code:
596200208
Publication Date:
February 2014
Latest Update Bulletin:
December 2014
Format:
PDF, 125 Pages
Price:
£7,725

HIV: KOL Insight examines what frontline clinicians really think about current HIV treatment pathways, addresses the most pressing unmet needs the industry can respond to and gives insight into what's driving long term growth in HIV.

Therapy Trends KOL Insight: HIV analyses the current and predicted key issues, current products and late-stage pipeline products. The report gives you qualitative, inside information from exclusive and detailed FirstWord interviews with 12 of the foremost key opinion leaders (KOLs) active in HIV treatment clinics in the US and Europe.

 

Key Takeaways

KOL Panel

Therapy Trends:HIV offers two comprehensive modules:
  • The KOL Insight: HIV module provides a complete review underpinned by exclusive in-depth interviews with 12 leading KOLs from the US and Europe
  • The Consensus Outlook: HIV data analysis module provides annual historical and forecast product-level sales data based on leading equity analysts' projections. Key findings are given in a written analysis to support the visual data analyses provided in charts and tables.
    • Available Report Options:
      • Therapy Trends: HIV, KOL Insight and Consensus Outlook
      • Therapy Trends: HIV, Consensus Outlook

Meeting the challenge of unmet need
Many of the challenges faced by clinicians are not related to efficacy, but include poor adherence to treatment, often exacerbated by societal and mental health issues, the stigma associated with diagnostic testing and low levels of early diagnosis. There are, however, opportunities for industry to improve patient outcomes.

Therapy Trends Reports deliver a deep level of unbiased insight from the world's foremost KOLs about the current and future treatment landscapes in key markets. Research is focused on the major battlegrounds for market share and answers critical business questions about potential product positioning and competitiveness. Through continuous monitoring and frequent re-engagement with KOLs after major events, FirstWord delivers three quarterly Update Bulletins with each report ensuring insights remain current and relevant.

Dr Jay Dobkin MD, Associate Attending Physician, Columbia-Presbyterian Hospital, New York, USA

Dr Monica Gandhi MD, Associate Professor of Clinical Medicine, UCSF, California, USA

Dr Edwin DeJesus MD, HIV Specialist and Medical Director, Orlando Immunology Center, Florida, USA

Dr. Joel Gallant MD, Associate Medical Director of Specialty Services, Southwest CARE Center - Santa Fe, New Mexico, USA

Dr Richard Haubrich MD, Professor of Medicine in the Department of Medicine, Division of Infectious Diseases, UCSD, California, USA

Dr Bruce Agins MD, Medical Director New York State Department of Health AIDS Institute, New York, USA

Dr Barry Peters, Consultant Physician, Guy's and St Thomas Hospital, London‏, England

Dr Magnus Gisslén, HIV Unit, Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden

Dr Jean-Michel Molina, Saint-Louis Hospital and University of Paris, France

Dr Pere Domingo Pedrol, Hospital Santa Creu I Sant Pau, Barcelona, Spain

Dr José Arribas, Hospital La Paz, Madrid, Spain

Anonymous German KOL

 

Key Features

Expert Opinion for Real World Insights
The data and analysis in the report is enriched through the specific insights and opinions of leading clinicians working in HIV in the US and Europe. Their views on specific drugs and treatment pathways provide a unique front line perspective from those working in a clinical setting. The results of these detailed and extensive interviews are incorporated throughout the text so they can be read in the context of the issue or product being discussed.

Key Features

  • Critical insights on products and market developments from leading US and European clinicians
  • Complete coverage of all therapeutic approaches
  • Assessment of current leading HIV products by class
  • Analysis of late-stage pipeline HIV therapies by class
  • Competitive evaluation of leading players
  • Current opinion and trends on the diagnosis and treatment of HIV
  • KOL predicted treatment trends and market leaders
  • Regular Update Bulletins sent to you when published
    • The August 2014 update includes information on ViiV Healthcare's Tivicay and Triumeq, Merck & Co.'s, Isentress, raltegravir/lamivudine, Gilead's Vitekta, Tybost, Janssen, Gilead's, Prezista/cobicistat

All current therapeutic approaches covered

  • Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)
  • Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
  • Integrase inhibitor
  • Protease inhibitor
  • CCR5 inhibitor

Products & Companies Covered

  • Truvada (tenofovir/emtricitabine); Gilead
  • Epzicom/Kivexa (abacavir/lamivudine); ViiV Healthcare
  • Atripla (tenofovir/emtricitabine/efavirenz); Gilead
  • Complera/Eviplera (tenofovir/emtricitabine/rilpivirine); Gilead
  • Reyataz (atazanavir); Bristol-Myers Squibb
  • Prezista (darunavir); Janssen Therapeutics
  • Kaletra (lopinavir/ritonavir); AbbVie
  • Isentress (raltegravir); Merck & Co.
  • Stribild (tenofovir/emtricitabine/elvitegravir/cobicistat); Gilead
  • Tivicay (dolutegravir); ViiV Healthcare
  • Selzentry/Celsentri (maraviroc); ViiV Healthcare

Key KOL Quotes

"We know that patients who are on therapy do better if they are taking one pill a day, as a combination pill, there is no question about that. We need the best possible fixed dose single combination pill."

"Every patient who takes the drugs will be able to suppress the virus, so the question is not the potency of the combination, the question is the toxicity in the long-term. What about the kidneys? I mean everybody is taking tenofovir. We see the renal problems after years. We have an aging (HIV) population and we have to be prepared for the long run and I don't think we really are."

"There are a lot of expectations with Trii. I cannot think of another drug where the expectations were as high. Trii could be a good option for many different patients, and you don't have to worry about the renal issues. It's highly potent, very well tolerated, it doesn't have a signature toxicity. I see a bright future for Trii."

"Current NNRTIs have a low barrier for resistance and a significant amount of patients are going to fail eventually with K103N [mutation]. Having an NNRTI that is able to overcome mutations is important."

"My personal view is that it will have a very small impact. We know PrEP with Truvada works. The major problem is cost. You need to give the medicines to plenty of uninfected subjects to prevent a few cases of HIV."

KOL Insight Update Bulletins Offer Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with regular Update Bulletins offers a real commercial advantage.

  • Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
  • Your Therapy Trends Report purchase includes access to Update Bulletins once published



customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved